Quest Diagnostics reported strong second-quarter results, exceeding Wall Street expectations for both earnings and revenue. The company also raised its full-year 2026 guidance, driven by broad-based volume growth and increasing demand for preventive healthcare tests.
Quest Diagnostics (DGX) delivered a significant beat on its Q2 earnings and revenue, surpassing analyst consensus. This strong performance was fueled by a 13.1% increase in total requisition volume, with organic volume up 13%, indicating robust demand across all customer channels, particularly in preventive healthcare. The company's decision to raise its full-year 2026 guidance for both EPS and revenue signals management's confidence in continued growth and operational efficiency. This positive outlook is a major catalyst for DGX, suggesting potential for further stock appreciation in the short term and reinforcing its long-term growth strategy in the diagnostic testing market. Traders should note the stock's new 52-week high, indicating strong market sentiment.